JP2021502350A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502350A5
JP2021502350A5 JP2020524598A JP2020524598A JP2021502350A5 JP 2021502350 A5 JP2021502350 A5 JP 2021502350A5 JP 2020524598 A JP2020524598 A JP 2020524598A JP 2020524598 A JP2020524598 A JP 2020524598A JP 2021502350 A5 JP2021502350 A5 JP 2021502350A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
composition according
weeks
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502350A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059233 external-priority patent/WO2019090238A1/en
Publication of JP2021502350A publication Critical patent/JP2021502350A/ja
Publication of JP2021502350A5 publication Critical patent/JP2021502350A5/ja
Priority to JP2023146339A priority Critical patent/JP2023175761A/ja
Pending legal-status Critical Current

Links

JP2020524598A 2017-11-03 2018-11-05 ジカワクチン及び免疫原性組成物、ならびにその使用方法 Pending JP2021502350A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023146339A JP2023175761A (ja) 2017-11-03 2023-09-08 ジカワクチン及び免疫原性組成物、ならびにその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US62/581,500 2017-11-03
US201762592995P 2017-11-30 2017-11-30
US62/592,995 2017-11-30
PCT/US2018/059233 WO2019090238A1 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146339A Division JP2023175761A (ja) 2017-11-03 2023-09-08 ジカワクチン及び免疫原性組成物、ならびにその使用方法

Publications (2)

Publication Number Publication Date
JP2021502350A JP2021502350A (ja) 2021-01-28
JP2021502350A5 true JP2021502350A5 (https=) 2021-12-02

Family

ID=64427224

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020544571A Active JP7295124B2 (ja) 2017-11-03 2018-11-05 ジカワクチン及び免疫原性組成物、ならびにその使用方法
JP2020524598A Pending JP2021502350A (ja) 2017-11-03 2018-11-05 ジカワクチン及び免疫原性組成物、ならびにその使用方法
JP2020524599A Active JP7443232B2 (ja) 2017-11-03 2018-11-05 ジカウイルスを不活化するため、及び不活化の完全性を決定するための方法
JP2023146339A Pending JP2023175761A (ja) 2017-11-03 2023-09-08 ジカワクチン及び免疫原性組成物、ならびにその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544571A Active JP7295124B2 (ja) 2017-11-03 2018-11-05 ジカワクチン及び免疫原性組成物、ならびにその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020524599A Active JP7443232B2 (ja) 2017-11-03 2018-11-05 ジカウイルスを不活化するため、及び不活化の完全性を決定するための方法
JP2023146339A Pending JP2023175761A (ja) 2017-11-03 2023-09-08 ジカワクチン及び免疫原性組成物、ならびにその使用方法

Country Status (12)

Country Link
US (6) US11730802B2 (https=)
EP (3) EP3703739A2 (https=)
JP (4) JP7295124B2 (https=)
KR (3) KR20200117981A (https=)
CN (3) CN111526885A (https=)
AU (6) AU2018359660B2 (https=)
BR (3) BR112020008693A2 (https=)
CA (3) CA3081578A1 (https=)
MX (3) MX2020004543A (https=)
MY (3) MY194449A (https=)
SG (3) SG11202003800YA (https=)
WO (3) WO2019090238A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200117981A (ko) * 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
MX2020005554A (es) * 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
BR112021019845A2 (pt) * 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン,インコーポレイテッド ジカウイルス特異的抗体の検出方法
EP4226155A1 (en) 2020-10-09 2023-08-16 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (zh) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 一种重组寨卡病毒减毒株及其制备方法和应用
CN112941201B (zh) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 一种用于多细胞种属鉴别和交叉污染检测的混合引物及其使用方法
EP4476329A1 (en) 2022-02-09 2024-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (ko) * 2022-12-27 2023-12-29 주식회사 그린백스 에피갈로카테킨-3-갈레이트에 의해 불활화된 지카바이러스를 유효성분으로 포함하는 백신 조성물
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0957972B1 (en) 1996-12-20 2003-03-19 Alza Corporation Device and method for enhancing transdermal agent flux
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DK1025209T3 (da) 1997-08-28 2007-06-25 Cheil Jedang Corp Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
EP1021548A1 (en) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
DE69935927T2 (de) 1998-12-02 2008-01-10 University Of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
JP3976685B2 (ja) 2000-11-22 2007-09-19 ユニバーシティ オブ メリーランド, ボルチモア タンパク質分泌のためのClyA溶血素の使用
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
RS20070078A (sr) 2004-08-27 2008-11-28 Panacea Biotec Ltd., Inaktivirana vakcina protiv poliomijelitisa nastala iz sabinovog soja polio virusa
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CN101516395B (zh) 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
CN101954076A (zh) 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
EP2714076A1 (en) 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
EP2720715B1 (en) 2011-06-17 2017-08-09 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2015059714A1 (en) 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
UA125788C2 (uk) 2014-10-07 2022-06-08 Серум Інстітют Оф Індія Прайвт Лімітед Спосіб інактивації ентеровірусу, ад'ювант адсорбції та композиція із зменшеною дозою вакцини, одержана з ним
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
BR112017027770A2 (pt) 2015-06-22 2018-09-11 Harvard College composições e métodos para modular infecção viral
EP3322441A4 (en) 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11111481B2 (en) 2015-09-30 2021-09-07 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved RNA structure
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
ES2973267T3 (es) * 2015-12-23 2024-06-19 Valneva Se Purificación de virus
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
AU2017222644B2 (en) 2016-02-25 2021-07-29 The Trustees Of The University Of Pennsylvania Novel vaccines against Zika virus
WO2017161151A1 (en) 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
WO2017197034A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
BE1024796B9 (fr) 2016-06-02 2019-01-08 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
BR112018075440A2 (pt) 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center composições e métodos para prevenir e tratar a infecção por zika vírus
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
BR112018077041A2 (pt) 2016-07-08 2019-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale sequências genômicas que codificam para um vírus da zika mutante atuado
WO2018022786A1 (en) 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
WO2018091540A1 (en) 2016-11-17 2018-05-24 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
WO2018165373A1 (en) 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
CN109081868B (zh) 2017-06-14 2022-06-24 中国科学院上海巴斯德研究所 靶向寨卡病毒包膜蛋白保守表位的单克隆抗体及其应用
WO2018237039A1 (en) 2017-06-20 2018-12-27 Texas Tech University System Zika virus like particle (vlp) based vaccine and microneutralization assay
EP3417943B1 (de) 2017-06-21 2020-02-12 Eppendorf AG Zentrifugenrotor mit abdichtung
CN107188935B (zh) 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
BR102017024030A2 (pt) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei Proteína recombinante imunogênica com antígenos de zika virus para vacina e seus usos
WO2019104157A1 (en) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
EP3755818A1 (en) 2018-02-22 2020-12-30 Nano4 Global, Lda Method for detecting flaviviridae
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
SG11202009147UA (en) 2018-03-29 2020-10-29 Emergex Vaccines Holding Ltd Vaccine compositions
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
WO2020017765A1 (ko) 2018-07-18 2020-01-23 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US12064476B2 (en) 2018-10-26 2024-08-20 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
BR112021019845A2 (pt) 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
WO2021262659A1 (en) 2020-06-22 2021-12-30 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Similar Documents

Publication Publication Date Title
JP2021502350A5 (https=)
Kovaiou et al. Age-related changes in immunity: implications for vaccination in the elderly
Weinberger et al. Vaccines for the elderly
Pichichero Improving vaccine delivery using novel adjuvant systems
CN110198736B (zh) 带状疱疹疫苗组合物
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
HU219808B (hu) Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
CA2080477A1 (en) Oral vaccine comprising antigen surface-associated with red blood cells
JP6067900B2 (ja) 改善された免疫反応を誘導するワクチン
JP2021505549A5 (https=)
JP2019195328A (ja) デングウイルスワクチンのための方法および組成物
Bhatnagar et al. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
JP2024520730A5 (https=)
US20170173146A1 (en) Attenuated Parvovirus Vaccine for Muscovy Duck Parvovirus and Goose Parvovirus (Derzsys Disease)
PH12022550939A1 (en) Chikungunya virus-like particle vaccine and methods of using the same
EP3785719A1 (en) New use of cyclic dinucleotides
EP3119428B1 (en) Toll-like receptor 2 agonists and vaccines and uses thereof
JP5846624B2 (ja) H5n1型インフルエンザワクチン及び感染防御キット
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
KR20140060053A (ko) 인플루엔자 백신용 면역증강제
EP4438047A1 (en) Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof
Liu et al. Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development
TH2001002475A (th) วัคซีนจากซิกาและองค์ประกอบอิมมูโนเจนิกและวิธีการใช้สิ่งดังกล่าว
Loughlin et al. Vaccines: Past, Present, and Future